{
    "url_original": "https://www.wsj.com/articles/moderna-beats-profit-estimates-fueled-by-vaccine-sales-11645707646?mod=business_lead_pos2",
    "url": "moderna-beats-profit-estimates-fueled-by-vaccine-sales-11645707646",
    "title": "Moderna Beats Profit Estimates, Fueled by Vaccine Sales",
    "sub_head": "Vaccine-maker is working on an Omicron-specific booster, but its stock has tumbled this year",
    "category_1": "Business",
    "category_2": "Earnings",
    "image_1_url": "https://images.wsj.net/im-491059?width=860&height=573",
    "image_1": "im-491059.jpg",
    "time": "2022-02-24 08:00:00",
    "body": "Moderna Inc.  posted better-than-expected profits for the last three months of 2021 as the company’s vaccine for Covid-19 continued to power its year-over-year growth.<br />In the latest quarter, Moderna’s revenue reached $7.21 billion, with nearly all of that coming from vaccine sales. The Cambridge, Mass., company said it distributed a total of 807 million shots last year."
}